GLP-1 receptor agonists, such as semaglutide (Ozempic®/Wegovy®) and tirzepatide (Mounjaro®), are a class of peptide drugs that mimic the naturally occurring GLP-1 hormone. They help regulate blood glucose, slow digestion and reduce appetite. Originally developed for type 2 diabetes, their dramatic weight-loss effect turned them into the fastest-scaling drug class in pharma history, despite being structurally complex peptides that are hard to mass-produce.

Download our position paper now and discover how GLP-1 receptor agonists became the fastest-scaling drug class in pharma history, and what it takes to produce these complex peptides at scale. Happy reading!